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Overview/Abstract 
Medications are developed by the pharmaceutical industry starting with the discovery 
phase, proceeds to preclinical trials, moves into clinical trials (progressing from Phase I 
to Phase III), and if the data are positive, may lead to Food and Drug Administration 
(FDA) approval. Once approved, post-marketing surveillance for safety is required as 
long as the drug is marketed to consumers. This phase may also include clinical trial 
Phase IV studies if additional safety testing is required. This process usually takes 
between ten to fifteen years, with clinical development taking seven to ten years of that 
time (1). Clinical development can be facilitated by a clinical development Project 
Management Office (PMO) at pharmaceutical companies. Clinical development PMOs 
provide value by establishing processes that can be universally adopted by the 
pharmaceutical industry. This can help simplify product development, and as a result, 
accelerate time to market. Clinical development project management is a relatively new 
field in the pharmaceutical industry, and there are few publications and literary reviews 
regarding standardized best practices, current best practices, and potential best 
practices for clinical development.  
Decreasing the time it takes a drug to reach market can help patients live longer and/or 
improve their quality of life. Time to market is often driven by the time it takes to test the 
product in clinical settings. This thesis is focused on analyzing the clinical development 
project management practices in order to reduce the time to market. The goals of this 
project were to identify best practices in clinical development project management, 
compile a reference standard, develop a rubric, evaluate the rubric on a comparator 
company, and make a recommendation regarding actions required for the comparator 
company to achieve the reference standard.   
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1. Introduction 
The beginning of the regulation of the pharmaceutical industry can be traced back to 
1938 when Congress passed the Federal Food, Drug, and Cosmetic Act (FDCA) law. 
The external landscape of the pharmaceutical industry and drug regulations have made 
big strides in the past 50-100 years due to various tragedies of the time. This included 
one of the first mass-deaths reported of over 100 patients due to a sulfanilamide 
medication used to treat streptococcal infections. The revised formulation used 
diethylene glycol (antifreeze) to dissolve the drug. This forced legislation to initially 
regulate safety (2). Regulations later followed regarding drug quality and efficacy. In 
order to bring a product to market, companies must first seek approval for testing in 
clinical trials (supported by scientific data), and if the results indicate a therapeutic 
benefit that outweighs any associated risks, then the company may seek approval to 
market the product. 
1.1 Drug Definition 
The term pharmaceutical products refers to medicines or drugs. According to the World 
Health Organization (WHO), it is important that prescribed products are of good quality, 
safe, effective and prescribed and used rationally (3). The Food and Drug Administration 
(FDA) defines drugs as any product that is intended to affect body structure or function 
for the purpose of diagnosis, treatment or prevention of disease (4). 
Pharmaceutical products can be classified as small molecules (chemical compounds), 
generics (non-branded version of a small molecule), biologics (produced by or part of a 
living organism) or biosimilars (non-branded version of an existing biologic). These 
products may also be available either as prescription only or over-the-counter (OTC), 
and may vary in the formulation (e.g., liquid or tablet) and routes of administration (e.g., 
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oral, nasal, or transdermal). Regardless of the classification or formulation, the approval 
process by the FDA is the same.  
The development of small molecule drugs for treating and preventing disease played an 
important role in the practice of medicine. The history of small molecules spans 
thousands of years with the use of naturally occurring extracts for medicinal purposes 
(e.g., aspirin), to present day de novo synthetic organic molecules for drug development 
(e.g., statins). This has contributed to the improvement of health and increased life 
expectancy (5).  
Generic drugs emerged in the United States in 1984 with the Drug Price Competition 
and Patent Term Restoration Act, also known as the Hatch-Waxman Act, which changed 
the pharmaceutical field by making it easier for generic drugs to enter the market (6). 
The FDA states that a generic drug product must be comparable to the reference drug in 
terms of strength, performance, safety, quality, method of administration, and dosage 
form. It is essential that the generic drug have the same intended use as the reference 
drug (7). 
The regulation of biological products began with the Biologics Control Act of 1902. 
Unlike traditional chemical manufacturing of drugs, biological products are isolated from 
living organisms. Biological products include vaccines, blood derivatives, and gene 
therapy products amongst others. Biologics are used in the treatment of cancer and 
other diseases (8). The most recent development is biosimilars, which are developed 
from living cells through highly complex manufacturing processes, but “similar” to 
another biologic already approved by the FDA. An example of a biosimilar is Zarxio 
(Filgrastim-sndz) (9) which was FDA approved in 2015 and is analogous to Neupogen 
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(Filgrastim).  Both drugs are prescribed to cancer patients following chemotherapy to 
help decrease the risk of developing neutropenia. 
1.2 FDA Drug Approval Process 
FDA ensures that the drugs on market, whether brand name or generic, are safe and 
effective, and that the health benefits outweigh the risks. The process begins at the 
discovery phase, proceeds to preclinical trials, moves into clinical trials (progressing 
from Phase I to Phase III), and if the data are positive, may lead to FDA approval. The 
life cycle management stage includes post-marketing surveillance for safety as long as 
the drug is marketed to consumers. Post-marketing may also include clinical trial Phase 
IV studies if additional safety testing is required. The discovery phase involves 
investigation of thousands of compounds as potential drug candidates. Once a 
promising compound is found, experiments are conducted to gather initial information on 
a number of factors, such as how it is metabolized, the potential benefits, dosage, 
administration, side effects, other drug interactions and effectiveness. Following 
discovery, further information on these factors are gathered through preclinical trials, 
which involve both in vitro and in vivo animal research to evaluate the new drug’s safety 
(e.g., toxicity) and efficacy. Following the data obtained from these tests, an 
Investigational New Drug (IND) application is submitted to the FDA that includes 
information on the drug composition, manufacturing, and clinical trial plan. The FDA 
reviews the IND to verify that the proposed studies, known as clinical trials, focus to 
ensure clinical trial subject safety. The FDA also verifies that there is informed consent 
and that human subject protections are in place prior to initiation of clinical trials. If the 
FDA feels that these criteria are met, the drug under investigation then moves to the 
clinical stage where the drug sponsor’s clinical trials are divided into Phases I, II, and III. 
In clinical trial Phase I, the focus is evaluating the safety of the drug, and traditionally 
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involves approximately 20-80 healthy volunteers with the goal of the identifying the 
drug’s side effects, and evaluating how the drug is absorbed, distributed, metabolized 
and excreted from the body. If the data captured in clinical trial Phase I are positive, the 
drug transitions into clinical trial Phase II, where traditionally the number of subjects 
increases into the hundreds.  The focus of clinical trial Phase II is learning more about 
the safety of the drug, including the maximum tolerated dose, and looking for initial 
efficacy signs in people who have the particular condition or disease. At the conclusion 
of clinical trial Phase II, assuming the data are positive, the FDA and drug sponsors 
discuss how the clinical trial Phase III studies will be designed and completed. In clinical 
trial Phase III, the patient numbers traditionally move into the thousands and the primary 
focus is to evaluate efficacy, along with continual assessment of safety. Following this 
phase, a meeting between the FDA and drug sponsor occurs before the submission of a 
New Drug Application (NDA). The NDA filing is requested by the drug sponsor to gain 
approval from the FDA to market the drug in the United States, supported by all the data 
gathered to date as outlined above. Following the receipt of the NDA, the FDA has 60 
days to evaluate whether the applicant has provided the information required for FDA 
review. If sufficiently complete, the FDA review team evaluates the sponsor’s data on 
drug safety and effectiveness. As part of the review process, the FDA will inspect the 
manufacturing facility(ies) and a subset of the clinical and nonclinical testing sites. If the 
FDA doesn’t evaluate the drug’s benefits outweigh the risks, they will issue a “Complete 
Response Letter”, which means that product cannot be sold in the US. The company 
can then choose to conduct further testing or not pursue the product at all. If the FDA 
deems that the benefits outweigh the risks, the FDA will negotiate the exact drug label 
with the sponsor to ensure important information is communicated to health care 
professionals and patients, and officially approve the product. As it is not possible to 
predict what happens after the drug is on the market, post-market surveillance of safety 
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is required. Further studies (clinical trial Phase IV) may also be required to also evaluate 
specific safety questions. The drug sponsor is also required to submit periodic safety 
updates to the FDA throughout the drug’s marketed life. In addition to sponsor safety 
reporting requirements, the FDA also provides a mechanism for physicians and patients 
to voluntarily report adverse events. Should post-marketing safety analysis identify new 
safety risks, product availability can be restricted (e.g., through a restricted access 
program, also known as Risk Evaluation and Mitigation Strategy or REMS) or in rarer 
cases, the drug can be withdrawn from the market. 
1.3 Time to Market 
In 2013, drug discovery products accounted for about 5,000-10,000 of potential products 
being developed. Of those potential products, only between 2.5% to 5% move to 
preclinical. Less than one-half of one percent of products investigated in preclinical 
stages are approved. The average time from discovery to market for drugs is ten to 
fifteen years, with a hefty portion of that time spent in clinical trials (six to seven years; 
Table 1).  
Table 1: Average time from discovery to market   
 Drug 
Discovery 
Preclinical Clinical Trials Approval and 
Launch 
Products in 
stage 
5,000 – 10,000 250 5 1 
Duration 3-6 Years 6-7 Years 0.5 – 2 Years 
Source: PhRMA, 2013 
 
The top five fastest drug developers average 3.9 to 4.6 years in clinical development 
Table 2 (1). The fastest developer (Abbott) leads the median clinical trial duration with 47 
months as opposed to the fifth fastest developer (BioMarin) at 55 months, almost a half-
year difference. Conversely, BioMarin leads with the shortest NDA approval median 
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duration (6 months), which is due to shorter review times for orphan drugs in comparison 
to other drugs. 
Table 2: 2014 Fastest drug developers  
 Median clinical 
duration (in months) 
Median NDA approval 
duration (in months) 
Total median duration 
(in months) 
Janssen 
(J&J) 
47 10 57 
Abbott 47 9 56 
Sanofi 51 13 64 
Shire 55 19 73 
BioMarin 55 6 61 
Source: CenterWatch, 2013 
 
Pharmaceutical companies face challenges through the lengthy drug development 
process (Figure 1). Not only is a pharmaceutical company looking to deliver a product 
quicker, they are often competing in a race against other companies to be the first in the 
market. This requires efficiency throughout the organization. The complex product 
development process from molecule to product involves the management of many 
business processes such as manufacturing, regulatory strategy, and clinical 
development.  
The analysis of best practices in pharmaceutical industry, specifically in clinical 
development, where the most time is spent, will help identify standard practices for 
efficient drug development. 
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Figure 1: Drug development lifecycle  
The drug development lifecycle starts with the discovery phase, proceeds to preclinical trials, and 
moves into clinical trials, progressing from Phase I to Phase III, and depending on the data, may 
lead to FDA approval. The life cycle management stage includes post-marketing surveillance for 
safety as long as the drug is marketed to consumers. Post-marketing may also include clinical 
trial Phase IV studies if additional safety testing is required. 
 
1.4 Project Management Role in Pharma 
Project management has been known to drive success in industries such as information 
technology (IT) and construction/engineering (10). In the last decade, project 
management has been adopted by some pharmaceutical sectors, e.g., devices, but not 
holistically (5). 
There are few publications and literary reviews regarding standardized best practices, 
current best practices, and potential novel best practices for clinical development project 
management in pharmaceuticals (11). Furthering the knowledge in this area is warranted 
and would facilitate bringing products to patients sooner without sacrificing quality.  
2 Objectives and Strategy 
The specific aims of the project were: 
I. Establish a reference standard for best practices (Phase I) 
II. Develop an assessment methodology (rubric) for the Project Management 
Offices to the reference as standard (Phase I) 
III. Evaluate the rubric (Phase II) using a comparator company 
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IV. Make recommendations for how the comparator company could achieve the 
reference standard (Phase II) 
This research study involved a three-fold approach: study design, qualitative exploratory 
research (Phase I), and quantitative confirmatory research (Phase II).  
3 Research Design and Methods 
3.1 Study Design 
The study design involved two phases. Phase I was qualitative and designed to define a 
reference standard and develop a rubric for the assessment of clinical development 
project management offices (PMOs). Phase II was quantitative and designed to perform 
an initial assessment of ability of the rubric to assess a comparator company’s 
conformance with the reference standard. 
3.2 Phase I: Reference Standard and Rubric Development 
3.2.1 Questionnaire Development 
Phase I began with the development of a pilot questionnaire with six, open-ended 
questions. It was tested on 10 people from Company “A” and revised for a final set of 14 
open-ended questions. The final questionnaire can be found in Section 8.2.2.  
3.2.2 Sample Group 
Following the development of the questionnaire, a sample group of respondents were 
identified from three sources: 1) LinkedIn (Sunnyvale, CA) using the search term “project 
management” 2) personal network referrals through the last question of the survey (“Do 
you have any network contacts you can share in assisting with this research?”), and 
3) Program and Portfolio Management (PPM) (New York, NY) Conference messaging 
platform Bizzabo.  
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3.2.3 Company Metrics 
The companies for which the sample respondents were employed were evaluated on 
four metrics to establish cutoffs for company size: 1) number of full-time employees, 
2) revenue (US$), 3) profitability, and 4) drug pipeline (count).  The number of 
employees needed to qualify as a large company was defined as >10,000, medium as 
1,000-9,999, and small as <1,000. The revenue amount needed to qualify as a large 
company was defined as >$10B, medium as $1B – $10B, and small as <$1B. The 
profitability size designation for a large company was defined as “Yes”, for medium was 
“Either” (meaning either Yes or No), and for small was “No”. The drug pipeline needed to 
qualify as a large company was defined as >20, for medium as 10 – 20, and for a small 
company as <10. Company size classification criteria are provided in Table 3. 
Table 3: Company size classification 
 Large Medium Small 
Number of employees >10K 1K – 10K <1K 
Revenues >$10B $1B – $10B <$1B 
Profitability (y/n) Y ? N 
Drug Pipeline >20 10 - 20 <10 
 
The companies were assigned a unique identifier because permission was not 
requested to use their company name for this study. To further aid maintaining 
anonymity, exact metrics obtained from Yahoo! Finance (New York, NY) were rounded. 
The mid-sized company with the largest number of potential respondents (41 people) 
was selected as the comparator company. Personnel at the comparator company were 
not contacted in Phase 1, but reserved for Phase II of the study.  
3.2.4 Data Collection 
An introductory e-mail message was sent to the potential pool of respondents to provide 
background regarding the interviewer and the desired outcome, as well as a request to 
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schedule a meeting to conduct the interview. One-hour interviews were conducted with 
the respondents from March to May 2017. Data were captured during the interviews by 
handwritten notes and post-meeting transcribed into a word processing document. 
3.2.5 Data Cleaning 
Raw data captured in the word processing document were converted to a spreadsheet 
and subsequently cleaned by correcting spelling errors, spelling out abbreviations and 
removing duplicate entries (deduplication). Following a consistency check for correct 
project management context, high frequency words were identified by requiring that the 
word or term must have occurred greater than 10 times in the raw data. False positives 
(i.e., terms included in the results erroneously, such as “that” and “what” being returned 
for the term “hat”) were removed (Figure 2 and Figure 3). 
 
 
Figure 2: Data collection through reference standard development 
Funnel structure depicting the process for reference standard development, starting with total 
words from interview raw data being narrowed to high frequency words, and then classified into 
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categories and subcategories to develop the final reference standard definition (denoted by the 
red band). 
 
 
Figure 3: Data cleaning and analysis process 
Diagram depicting the process for data cleaning (from collection, data entry, deduplication to 
consistency check) and data analysis (categorization). 
 
3.2.6 Data Analysis 
Analysis involved grouping high-frequency words into categories, sub-categories and 
sub-sub categories, terms and attributes (the classification scheme outline and 
definitions can be found in Section 8.1). These groupings were reviewed holistically for 
consistency and correct categorical context (Figure 3). 
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3.2.6.1 Statistical Analysis 
To evaluate whether there was a difference in results based on company size, the data 
analysis tool in Microsoft Excel 2013 (version 15.0, Redmond, WA) for an ANOVA: Two-
Factor without Replication statistical analysis was used.  
3.2.7 Reference Standard and Rubric Development 
The reference standard was developed by applying a cutoff to the high frequency words. 
The numbers for the highest frequency word in each of the four top level categories were 
totaled, then divided by four (for the number of categories), and subsequently divided by 
four again to separate into quartiles, and then rounded to the nearest whole number. 
This method was selected over the use of the absolute count of the term in order to filter 
out terms that fell in the bottom quartile. The high frequency words meeting the cutoff 
became the terms that comprised the reference standard. 
The rubric was developed by creating actionable descriptions (i.e., attributes) of the 
terms in the reference standard. The descriptions were taken from the Phase I 
interviews.  
3.3 Phase II: Rubric Evaluation and Comparator Company Recommendations 
The Phase II objectives were to evaluate the rubric and make recommendations for how 
a comparator company could achieve the reference standard.  
3.3.1 Questionnaire Development 
The rubric developed in Phase I was converted into a Likert scale questionnaire which 
asked to what degree the respondent felt each attribute was being practiced at their 
company on a five-point scale (Strongly Disagree [1], Disagree [2], Neither [3], Agree [4], 
or Strongly Agree [5]). 
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3.3.2 Sample Group 
During Phase I (Section 3.2.2), the mid-sized company with the largest potential pool of 
respondents was reserved for Phase II. A mid-size company was thought to be a 
suitable comparator company as it would incorporate elements of both large and small 
companies.  
3.3.3 Data Collection 
A LinkedIn message was sent to the potential pool of respondents introducing the 
objective of the study and a link to the questionnaire in SurveyMonkey® (San Mateo, 
CA; Section 8.2.3). The message was sent and all responses were completed in 
April 2018. 
3.3.4 Data Analysis 
An average company was defined as a company performing at its sizing class, which is 
arbitrarily set with baselines that were neither too high nor low. To translate into a 
measurable metric on the Likert scale 5-point scale, numeric results from each top level 
cat average was totaled and >3.0 cutoff was set which is the mean of a 5-point scale. 
The cut-off was also required to evaluate the comparator company after the survey was 
conducted to set performance baselines for activities being/not being practiced.  
4 Results 
4.1 Phase I: Reference Standard and Rubric Development 
The objectives of Phase I were to develop a reference standard and associated rubric 
for the assessment of clinical development PMOs. 
4.1.1 Response Results 
A total potential pool of 127 respondents was identified from three sources: 1) LinkedIn 
(n=79), 2) referrals (n=29), and 3) Project and Portfolio Management (PPM) conference 
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messaging platform Bizzabo (n=19). Of the 127 potential respondents contacted, 
23 people expressed interest and received a copy of the final questionnaire comprised of 
14 questions. Seventeen of 23 completed the questionnaire with two (3%) from LinkedIn, 
eleven (38%) from referrals, and four (21%) from Bizzabo. The response rate was 12%, 
65%, and 24% for LinkedIn, referrals, and Bizzabo, respectively.  The overall response 
rate was 13% (Table 4). This response rate was lower than what was previously 
reported in a study where surveys of individuals had an average response rate of 53%, 
while surveys of organizations had an average response rate of 36% (12). 
Table 4: Participant pool, respondents, and overall percent per platform 
Platform Potential Pool Actual 
Respondents 
Response % Overall % 
LinkedIn 79 2 3% 11.76% 
Referrals 29 11 38% 64.71% 
PPM Bizzabo 19 4 21% 23.53% 
Total 127 17 13% 100% 
 
4.1.2 Company Metrics 
The 17 respondents were from 15 companies, with three respondents from the same 
company. The 15 companies were evaluated based on the criteria set in Section 3.2.3, 
with four classified as large, five as medium and seven as small (Table 5). 
Table 5: Number of responses by company 
Company size Total number of interview 
respondents 
Total number of companies 
Large 6 4 
Medium 4 4 
Small 7 7 
Total 17 15 
Source: Yahoo!Finance, 2017 (13) 
 
Evaluating each company’s revenue and drug pipeline against the number of full-time 
employees (FTE) provides metrics to measure their performance relative to their peers. 
For example, of the four companies classified as large, Companies 1 and 2 have a 
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revenue/FTE value of $600K each, while Companies 3 and 4 have a revenue/FTE value 
of $1M each, implying that Companies 3 and 4 are performing better relative to 
Companies 1 and 2. The pipeline/FTE ratio of Company 1 is 0.0006, for Companies 2 
and 3 are 0.001, and for Company 4 is 0.002, implying that Company 4 is performing 
better than the other three companies (Table 6). 
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Table 6: Company metrics of respondents 
Company ID FTE Revenue 
(US$) 
Profitable Drug 
Pipeline 
Size 
Classification 
Respondents Revenue/ 
FTE (US$) 
Pipeline/ 
FTE 
1 90,000 60B Y 50 Large 3 600K 0.0006 
2 30,000 20B Y 40 Large 1 600K 0.001 
3 30,000 30B Y 40 Large 1 1M 0.001 
4 20,000 20B Y 40 Large 1 1M 0.002 
5 9,000 30B Y 40 Medium 1 3.3M 0.004 
6 8,000 6B Y 10 Medium 1 750K 0.001 
7 1,000 500M N 10 Medium 1 500K 0.01 
8 1,000 2B N 20 Medium 1 2M 0.02 
9 500 3M N 10 Small 1 6K 0.02 
10 300 300M Y 10 Small 1 1M 0.03 
11 200 NA NA 10 Small 1 NA 0.05 
12 100 1M N 5 Small 1 10K 0.05 
13 100 10M N 10 Small 1 100K 0.1 
14 100 NA NA 1 Small 1 NA 0.01 
15 100 NA N 10 Small 1 NA 0.1 
Source: Yahoo!Finance 2017 (13) 
FTE = full-time employees 
NA = Not available 
Drug Pipeline = set of drug candidates that a pharmaceutical company has under discovery or development and any given point in time. 
   
 
17 
4.1.3 Categorization Overview 
The 17 interviews culminated in a total of 5,712 words relevant to project management 
context, which were further cleaned using the method outlined in Section 3.2.5, resulting 
in 540 high frequency words.  The high frequency words were then grouped into four top 
level categories: 1) Soft Skills, 2) Hard Tools, 3) Organizational Structure, and 4) PMO 
Components. Each of the categories had multiple sub-categories and sub-subcategories 
(Table 7).  
The Soft Skills category had 14 sub-categories (alphabetical, number of terms per 
category indicated in parenthesis after the term): Collaboration (8), Communication (54), 
Experience (9), Flexibility/Versatility (12), General (9), Humility (1), Innovative (6), Looks 
after best interests of project (1), Reading People (3), Relationship Building (6), Strategy 
(14), Tact and Diplomacy (2), Team Management (8), and Trust (9). The 54 terms in 
Communication were divided into four sub-subcategories: General (24), Project 
Management (PM) Specific (20), Processes (3) and Team Management (7). The Soft 
Skills sub-categories included in the reference standard were Communication (the three 
sub-subcategories of General, PM Specific and Team Management), Experience, 
General and Strategy. 
The Hard Tools category had two sub-categories: Processes (128) and Technology (29). 
The 128 terms in Processes were divided into 10 sub-subcategories: Budget (32), 
Contracting (1), Deliverables Management (8), General (10), Lifecycle Management (2), 
Matrices (4), Meeting Management (16), Resource Management (15), Technology 
Strategy (5), Timelines (18), and Training (17). The 29 terms in Technology were divided 
into nine sub-subcategories: Collaboration (2), Communication (5), Dashboards (6), 
Deliverables Management (1), Document Control (6), Hardware (1), Lifecycle 
Management (1) PPM (2), and Timelines (5). Although Timelines are found in both the 
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Processes and Technology sub-categories, they are defined differently, where Timelines 
in Processes is defined as creating timelines and Timelines in Technology is defined as 
a tool, such as a Gantt chart. The Hard Tools sub-category Processes included in the 
reference standard were Budget, Deliverables Management, Meeting Management, 
Resource Management, Timelines, and Training. There were no Technology sub-
categories included in the reference standard. 
The Organizational Structure category had 10 sub-categories: Alliance Management 
(14), Constraints (14), Culture (6), Efficiencies (14), General (12), Governance (34), 
Integration (4), Matrix Organization (26), Silo Organization, (3), and Transparency (2). 
The 14 terms in Constraints were divided into two sub-subcategories: General (9) and 
Turnover (5). The 26 terms in Matrix Organization were divided into three sub-
subcategories: General (8), PM Role (7), and Teams (11). The Organizational Structure 
sub-categories included in the reference standard were Alliance Management, 
Efficiencies, General, Governance, and the Teams sub-subcategory of Matrix 
Organization. 
The PMO Components category had five sub-categories: Alignment (13), General (5), 
Methodologies (17), PM Role (62), and Portfolio Management (6). The 62 terms in PM 
Role were divided into four sub-subcategories: General (44), Leadership (2), Strategic 
(11), and Tactical (5). The PMO Components sub-categories included in the reference 
standard were Alignment, Methodologies, and PM Role (with two sub-subcategories 
General and Strategic).  
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Table 7: Categorization overview (alphabetical) 
Category (n) Sub-categories (n) Sub-subcategories (n) 
Soft Skills (14) 
 
 
 
 
 
 
 
 
 
Collaboration (8)  
Communication (54) N=4: General (24), PM Specific (20), 
Processes (3), Team Management (7) 
Experience (9)  
Flexibility/Versatility (12)  
 
General (9)  
Humility (1)  
Innovative (6)  
Looks after Best Interests of 
Project (1) 
 
Reading People (3)  
Relationship Building (6)  
Strategy (14)  
Tact & Diplomacy (2)  
Team Management (8)  
Trust (9)  
Hard Tools (2) Processes (128) N=10: Budget (32), Contracting (1), 
Deliverables Management (8), General (10), 
Lifecycle Management (2), Matrices (4), 
Meeting Management (16), Resource 
Management (15), Technology Strategy (5), 
Timelines (18), Training (17) 
Technology (29) N=9: Collaboration (2), Communication (5), 
Dashboards (6), Deliverables Management (1), 
Document Control (6), Hardware (1), Lifecycle 
Management (1), PPM (2), Timelines (5) 
Organizational 
Structure (10) 
Alliance Management (14)  
Constraints (14) N=2: General (9), Turnover (5) 
Culture (6)  
Efficiencies (14)  
General (12)  
Governance (34)  
Integration (4)  
Matrix Organization (26) N=3: General (8), PM Role (7), Teams (11) 
Silo Organization (3)  
Transparency (2)  
PMO 
Components 
(5) 
Alignment (13)  
General (5)  
Methodologies (17)  
PM Role (62) N=4: General (44), Leadership (2), Strategic 
(11), Tactical (5) 
Portfolio Management (6)  
*Items indicated in Bold were included in the reference standard definition 
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4.1.3.1 Overview of Categories 
When looking at the aggregated results, the distribution across the four categories was 
fairly even. Soft skills and Organizational Structure were 26% each, Hard Tools and 
PMO components were 29% and 19%, respectively (Figure 4).  
To determine whether company size affected the distribution, the four categories were 
analyzed by company size (Section 4.1.2). The category distribution for large companies 
was 21% for Soft Skills, 35% for Hard Tools, 26% for Organizational Structure, and 18% 
for PMO Components. The category distribution for medium companies was 25% for 
Soft Skills, 37% for Hard Tools, 18% for Organizational Structure and 20% for PMO 
Components. The category distribution for small companies was 32% for Soft Skills, 
19% for Hard Tools, 28% for Organizational Structure and 21% for PMO Components. 
ANOVA: Two-Factor without Replication statistical analysis of these results found no 
statistical significance, with a p-value of 0.41 (Figure 4 and Table 8). Thus, results were 
only analyzed at the overall level, not by company size. 
  
Figure 4: Top level category distribution overall and by company size  
Top level category distribution overall and by company size (large, medium, and small). ANOVA 
analysis found no statistically significant difference in the distribution based on company size 
(p-value = 0.41). 
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Table 8: Statistical analysis of top level category distribution by company size 
ANOVA: Two-Factor Without Replication 
   
SUMMARY Count Sum Average Variance 
  
Soft Skills 3 78 26 31 
  
Hard Tools 3 91 30.33333 97.33333 
  
Organizational 
Structure 
3 72 24 28 
  
PMO Components 3 59 19.66667 2.333333 
  
       
Large 4 100 25 55.33333 
Medium 4 100 25 72.66667 
  
Small 4 100 25 36.66667 
  
ANOVA 
      
Source of 
Variation 
SS df MS F P-value F crit 
Rows 176.6667 3 58.88889 1.113445 0.414591 4.757063 
Columns 0 2 0 0 1 5.143253 
Error 317.3333 6 52.88889 
   
Total 494 11 
    
SS: Sum of squares 
Df: Degrees of freedom 
MS: Mean squares 
F: F Statistic, variance of the group means (Mean Square Between)/mean of within group variances (Mean 
Squared Error) 
F-crit: Probability value can occur (p value less than alpha) 
 
The overall category distribution for three of the top level categories (Soft Skills, Hard 
Tools, and PMO Components) had a single sub-category distinctly larger than the rest of 
their sub-categories, while Organizational Structure showed a more even distribution 
across sub-categories. The distribution of sub-categories (from highest to lowest) for 
Soft Skills was 38% for Communication, 10% for Strategy, 8% for Flexibility/Versatility, 
6% each for Collaboration, Experience, General, Team Management and Trust, 4% for 
Innovative and Relationship Building, 2% for Reading People and 1% each for Humility, 
Looks after Best Interests of the Project and Tact and Diplomacy. The Hard Tools sub-
category distribution was 82% for Processes and 18% for Technology. Organizational 
Structure sub-category distribution was 26% for Governance, 20% for Matrix 
Organization, 11% each for Alliance Management, Constraints, Efficiencies, 9% for 
General, 5% for Culture, 3% for Integration, 2% each for Silo Organization and 
Transparency.  PMO Components sub-category distribution was 60% for PM Role, 17% 
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for Methodologies, 13% for Alignment, 6% for Portfolio Management, and 5% for 
General (Figure 5). 
 
Figure 5: Sub-category distribution by top level category overall 
The sub-category distribution overall for three of the top level categories (Soft Skills, Hard Tools and PMO 
Components) had a single sub-category distinctly larger than the rest of their sub-categories while the sub-
categories for Organizational Structure were more evenly distributed 
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4.1.4 Reference Standard Definition 
The objective of the reference standard definition was to create a rubric that could be 
used by pharmaceutical companies to evaluate and improve clinical development project 
management performance. The initial list of categories (including sub and sub-
subcategories) totaled 65. Definition of each category with three to seven attributes 
would have produced a reference standard with hundreds of attributes, which was 
deemed too large to be usable. To produce a more manageable reference standard, a 
cutoff of ≥ 6 (Section 3.2.7) was applied resulting in 21 categories (indicated in bold in 
Table 7). These categories were then defined using words taken directly from the 
respondent interviews in Phase I to produce a total of 72 attributes (Section 8.3.2).  
Use of the cutoff of ≥ 6 (Section 3.2.7) resulted in certain terms with higher absolute 
values not being included. For example, in the Soft Skills category, Flexibility/Versatility 
had a total count of 12 terms. However, when distributed by company size, they all fell 
into the bottom quartile: large (5), medium (2), and small (5), and so did not reach the 
cut-off (>6).  Experience, on the other hand, had a total of 9 terms. The company size 
distribution was large (0), medium (8), and small (1). The medium count of eight fell 
above the >6 cut-off (i.e., outside the bottom quartile), so was included in the reference 
standard definition. The same was applied to the remaining top level categories (Hard 
Tools, Organizational Structure, and PMO Components). The individual categories had 
variable number of sub-subcategories and some sub-categories with additional context 
required a third level of categorization. Raw data for the word counts, organized by 
category (and sub and sub-sub) and company are provided in Table 19. 
4.1.5  Reference Standard Rubric 
The reference standard definition (72 attributes) was then converted into 72 actionable 
statements, i.e., the reference standard rubric, Section 8.3.2). 
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4.2 Phase II: Rubric Evaluation and Comparator Company Recommendations 
The Phase II objectives were to evaluate the rubric and make recommendations for how 
a comparator company could achieve the reference standard.  
4.2.1 Response Results 
Of the total potential pool of respondents of 41 people contacted via LinkedIn, 22 people 
expressed interest and received a copy of the 5-point Likert scale survey comprised of 
72 questions (see Section 3.3.1). Of the 22 that expressed interest, six respondents 
completed the survey (27% response rate). For Soft skills, which had 22 attributes, all of 
the responses were above the 3.0 cut-off, with the mean (median) of the six responses 
ranging from 3.6 – 4.5 (3.5 – 4.5). None of the six respondents Strongly Disagreed. 
There was one Disagree response each for three attributes (information sharing is 
concise, information sharing is precise, and PMs are effective at ensuring issues are 
appropriately shared across teams). Hard Tools had 24 attributes, with the mean 
(median) of the six responses ranging from 2.5 – 4.0 (2.5 – 4.0). Four of the Hard Tools 
attributes were below the 3.0 cut-off. Four of six respondents Strongly Disagreed with 
four attributes (Organization Tracks Actuals Against Budget, Team Members are Kept to 
a Minimum, PM Training Leverages Project Management Body of Knowledge [PMBOK], 
and Organization Provides Just-in-Time [JIT] Training [i.e., relevant training is provided 
just before needed]). There were Disagree responses for all but three attributes. 
Organizational Structure had 14 attributes, with the mean (median) of the six responses 
ranging from 2.8 – 3.8 (3.0 - 4.0). All of the responses for Organizational Structure 
attributes were above the 3.0 cut-off. None of six respondents Strongly Disagreed. 
Neither agree nor disagree responses accounted for a majority of responses. PMO 
components had 11 attributes, with the mean (median) of the six responses ranging from 
2.5 – 4.2 (2.5 – 4.0). All but one of the responses for PMO components attributes were 
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above the 3.0 cut-off. One of six respondents Strongly Disagreed with one attribute 
(organization leverages PMBOK practices). There were four Disagree responses for 
three attributes (PMs ensure portfolio and product strategies are developed, PMs help 
teams to think strategically, organization leverages PMBOK practices, and PMs assist in 
establishing agreed upon product development plans).  
4.2.2 Data Analysis 
In order to evaluate the usability of the rubric, four factors were analyzed: 1) response 
rate, 2) completion rate, 3) completion time and 4) response variation. The survey 
response rate was 27%, which was higher than the response rate from LinkedIn 
(11.76%), lower than the response rate from referrals (64.71%) and comparable with the 
response rate for the Bizzabo platform (23.53%). All of the respondents (n=6) that 
started the survey, completed it. The time for completion ranged from 7:01 minutes to 
51:12 minutes, with five out of six respondents’ completion times under 17 minutes. The 
average completion time of all the respondents was 18 minutes, and was 11:34 minutes 
if the one outlier (51:12 minutes) was excluded. Responses were varied both within each 
individual respondent’s results and across respondents, i.e., no respondent answered all 
statements with the same value, nor did any respondents answer all questions 
identically.  
In order to evaluate the performance of a comparator company relative to the 
expectations of an average company (defined as a score of 3.0), the overall mean and 
median values of the survey results were calculated for each of the four categories. 
The mean (median) for Soft Skills was 4.8 (4.0), for Hard Tools 3.9 (3.4), Organizational 
Structure 3.9 (3.4) and PMO Components 4.3 (4.3) (Table 9 and Supplementary 
Table 19). 
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Table 9: Comparator company overall mean and median values 
 Soft Skills Hard Tools Organizational 
Structure 
PMO 
Components 
Mean 4.8 3.9 3.9 4.3 
Median 4.0 3.4 3.4 4.3 
 
The comparator company, a mid-sized company identified in Phase I and reserved for 
Phase II testing (Section 3.2.3) had 7,300 employees with a revenue of $12B, and was 
profitable with 17 products in the pipeline (Table 10).  
Table 10: Comparator company size evaluation 
 Medium Comparator Company 
Number of employees 1K – 10K 7,300 
Revenues $1B – $10B $12B 
Profitability (y/n) Y or N Y 
Pipeline 10 - 20 17 
Source: Yahoo!Finance 2017 (13) 
 
5 Discussion 
The objectives of Phase I were to define a reference standard and develop an 
associated rubric for the assessment of clinical development PMOs. The Phase II 
objectives were to evaluate the rubric and make recommendations for how a comparator 
company could achieve the reference standard.  
5.1.1 Phase I: Reference Standard and Rubric Development 
Each of the four top level categories had themes. Soft Skills had three themes: 
Communication, Strategy, and Experience. Hard Tools themes centered on Processes, 
with sub-themes of Budget, Deliverables Management, Meeting Management, and 
Resource Management, Timelines, and Training. Although Timelines are found in both 
subcategories (Processes and Technology), they are defined differently, where 
Timelines in Processes is defined as creating timelines and Timelines in Technology is 
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defined as a tool, such as a Gantt chart. Organizational Structure had themes around 
Governance, Efficiencies, and Teams. PMO Components included themes around the 
PM Role, Methodologies and Alignment (Figure 5). 
Although Soft Skills had three themes (i.e., Communication, Strategy, and Experience), 
the theme of Communication was dominant, representing more than one-third of the 
attributes (38%). This reveals not only the need for good communication, but how easily 
poor communication can become an issue. The reference standard provides best 
practices needed to effectively communicate by specifying the attributes required, e.g., 
direct, concise, and precise. 
The Hard Tools themes focused on processes, accounting for 82% of the terms for this 
category, highlighting the difficulty in achieving good processes. The processes 
necessarily incorporate technology (which is important to meet specific needs), however, 
technology alone cannot meet all the needs. Therefore, a focus on processes for 
budgeting, training, and resource management are important as best practices.  
The Organizational Structure themes were Governance (26%), Efficiencies (11%) and 
Teams as part of a Matrix Organization (20%). The data suggest that Governance is 
important because of its role in decision making. Therefore, a focus on Governance 
ensures that the organization has specific decision making and escalation pathways. 
Efficiencies focused on reducing the amount of time that processes required and on 
ensuring that “trains run on time”. Data on Teams as part of Matrix Organization focused 
on the need for teams to manage the project (called “project teams”).  
The PMO Components category had themes around the PM Role (62%), Methodologies 
(17%) and Alignment (13%). The data suggest that an important component to a PMO is 
the organization’s understanding of what the project manager does and how their role 
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fits into the overall team structures. Methodologies focused on the importance of 
leveraging the Project Management Body of Knowledge (PMBOK) from the Project 
Management Institute (PMI). Alignment focused on ensuring that the organization was 
internally aligned, and highlighted the importance of establishing agreed upon goals and 
objectives. 
The results reveal that the four top level categories can be grouped into two 
designations: “individual” and “organizational”. Soft Skills and Hard Tools fit into the 
“individual” designation because these categories are performed by an individual. 
Organizational Structure and PMO Components fit into the “organizational” designation 
because they are performed at the company level. For example, General 
Communication in Soft Skills consists of attributes of concise and direct communication. 
Although that could be considered an organizational designation (since all-around 
communication is important), the skill must first occur at an individual level in order for 
communication to impact the level of the organization. Organizational Structure includes 
Governance, which can only occur at a company level.  
5.1.2 Phase II: Rubric Evaluation and Comparator Company Recommendations 
The Phase II objectives were to evaluate the rubric and make recommendations for how 
a comparator company could achieve the reference standard.  
The evaluation of rubric usability involved four factors: 1) response rate, 2) completion 
rate, 3) completion time and 4) response variation. The response rate was 27%, which is 
on the higher end of what was seen in Phase I for non-referrals (none of the 
respondents were referrals). All of the respondents that started the survey, completed it, 
indicating that they were not deterred by the survey despite it being comprised of 72 
questions. Five out of six respondents required less than 12 minutes to complete the 
survey, indicating that the time required for completion was not onerous. There were 
   
 
29 
variations in the responses selected (both individually and across the sample group), 
indicating that respondents read the statements before responding.  
The rubric was used to evaluate a comparator company’s performance relative to the 
reference standard and whether that aligned with its performance relative to its peers. 
Based on the reference standard, the comparator company was ranked as performing 
above average in all Soft Skills attributes. Four attributes in Hard Tools were identified 
as needing additional work: 1) clear processes for adding resources and/or changing 
priorities, 2) organization-wide timeline templates with standard durations, 3) PM training 
to leverage PMBOK, and 4) organization-provided JIT training. One attribute each in 
Organizational Structure (the organization has the right-sized infrastructure in place), 
and PMO Components (the organization leverages PMBOK practices) were also 
identified as needing additional work.  
In theory, the reference standard rubric should reflect whether the performance of the 
company is at, above or below its performance measures relative to its peers. Based on 
the company metrics established in Section 4.1.2 and the mean and median analysis in 
Section 4.2.2, the comparator company appears to be doing incrementally better than 
average mid-sized companies, which is consistent with the Phase II results in Table 10. 
5.1.3 Limitations and Future Research 
As with all research, there are limitations to this study. One example is geographical, as 
all the respondents were solely from the West coast of the United States (US). 
Therefore, it is unknown whether this information will hold true for other regions of the 
US and/or for other countries. Both Phase I and Phase II sample groups were small so 
the findings could change with larger cohorts. For example, “Soft Skills’, Team 
Management” doesn’t appear for small size companies. This might be an artifact of the 
small sample size or it might be replicated in a larger cohort and thus identified as an 
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area worth further exploration. Finally, the study was not able to comprehensively 
evaluate and/or validate the accuracy and precision of the rubric, company metrics 
definition, and the cut-offs. As the ultimate goal is to decrease the amount of time for 
clinical development in pharmaceutical companies, one way to determine whether the 
reference standard is causative rather than solely correlative would be to measure 
clinical development time pre- and post-implementation of the reference standard.  
6 Conclusion 
The objective of all projects is to be on time, on budget, and within scope. In clinical 
development, that means safety and effectiveness within the intended population as 
quickly as possible. Average time to market for a drug in development is ten to fifteen 
years, and of that, seven to ten years are spent in clinical development. While a general 
project management standard for PM methodologies and techniques is outlined in the 
PMBOK by the PMI and best practices outlined for many industries, there are no current 
publications supporting project management in clinical development nor current 
performance measures based on clinical development project management best 
practices. Hence there is a need for defining best practices for clinical development 
project management. To meet this need, Phase I defined a reference standard and 
actionable guide (rubric) for the assessment of clinical development PMOs. The Phase II 
evaluated the usability of the rubric as a tool for identifying areas of strength and 
opportunity for clinical development project management best practices. Although further 
work is necessary, this research sets the foundation for more effectively leveraging 
clinical development project management to expedite bringing products to patients. 
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8 Appendix 
8.1 Reference Standard Classification Scheme 
The reference standard classification scheme uses the following hierarchy: 
• Category – highest level in the scheme, total of four 
o Sub-category – groupings within categories 
 Sub-subcategory – groupings within sub-categories 
• Term – actual word taken from Phase I interviews. 
Reference Standard at this level (subset of total items). 
o Attribute – Description of term created using 
information taken from Phase I interviews. Rubric at 
this level (limited to terms in Reference Standard). 
8.2 Interview Questions 
8.2.1 Study Design 
Questions: 
1. What does the Center of Excellence mean to you? 
2. What best practices/strategies do you employ to successfully complete your 
tasks? 
3. What pitfalls do you avoid & how? 
4. Tell me a little bit about your career path, how did you move into PM? 
5. Based on your current experience in the field, what have you done differently to 
be more productive or to stay ahead of the game? 
6. Do you have any internal or external contacts you can share in regards to 
assisting with my COE Research? 
 
8.2.2 Phase I 
Questions: 
1. What does a Project Management Center of Excellence mean to you? 
2. What PPM best practices/strategies have you personally observed (or perhaps 
used) that were helpful in teams/work streams to completing tasks and/or 
deliverables? 
3. Are there specific pitfalls you have observed when trying to implement 
project/portfolio practices at companies you’ve been a part of? Some pitfalls may 
be situations such as: Undefined goals, scope changes, lack of accountability, 
lengthy decision-making processes, issues with change management, or lack of 
communication. 
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4. What difficulties with interpersonal interactions in team dynamics have you 
observed and were there specific tools and techniques you have seen project 
managers apply to avoid or resolve difficulties?  
5. Regarding the PM’s you’ve worked with, are there certain types of backgrounds 
or characteristics that the most effective PM’s share? 
6. Based on your current experience in the field, what have you done differently to 
be more productive or to stay ahead of the game? 
7. What has your company done differently to be ahead in terms of innovation and 
creativity in PPM? 
8. What best practices/strategies/toolkits does your company leverage to 
successfully complete tasks? 
9. What are some PPM best-practices you’ve experienced with previous 
employers?  
10. What are best-practices you noticed were different (yet positive) from standard 
practices at your current employer? 
11. Based on your industry experience, what do you feel companies do well in 
regards to PPM? How do they do those things? 
12. What and how would you like to do things differently in a Project Management 
Office if given the opportunity? 
13. Do you have any internal or external PPM contacts you would be willing to share 
for participation in this survey? 
14. What tools, best practices, systems or rules would you include in a Project 
Management Center of Excellence? 
 
8.2.3 Phase II 
Likert-scale Survey Questions: 
Soft Skills 
1. Communications in my organization are direct and to the point without being rude 
2. Messages are tailored to the audience 
3. Messages are conveyed with humility 
4. Humor is used appropriately in communications 
5. Information is shared in a timely manner 
6. Information sharing is concise 
7. Information sharing is precise 
8. PMs are effective at communicating information internally and externally (e.g., 
teams, management, outside company, etc.) 
9. PMs are effective at communicating constraints and potential solutions 
10. PMs are effective at ensuring issues are appropriately shared across teams 
11. PMs are able to effectively share the pros and cons of mitigations 
12. PMs have real-time, high level knowledge of the project 
13. PMs are able to effectively communicate bad news 
14. PMs regularly check in with stakeholders 
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15. PMs leverage multiple communication methods effectively to obtain responses 
from team members 
16. PMs check the "pulse" of the team during meetings 
17. PMs are able to guide team meeting discussions so they remain constructive and 
productive 
18. Programs are prioritized at a portfolio level 
19. Trade-off decisions factor in both program and portfolio levels 
20. Competitive intelligence is used to inform portfolio and product strategy 
21. Organization provides opportunities for both formal training and hands on 
experience (including feedback) 
22. Soft skills are highly valued  
 
Hard Tools 
23. My organization has a current annual budget and five-year plan 
24. Projects are funded based on probability of success at the portfolio level 
25. Organization tracks actuals against budget 
26. Cost modeling & forecasting is used to inform budget and five-year plan 
27. Projects have clearly identified deliverables 
28. Responsibility for project deliverables is clearly identified 
29. Delivery of project deliverables is tracked against internal and external 
commitments 
30. Clear process for escalating potential delays in meeting project deliverables per 
internal and external commitments 
31. Team members are kept to a minimum 
32. Meeting agendas and minutes are developed and distributed in a timely manner 
33. Action Item, Decision and Issues (ADI) logs are maintained 
34. Risks are documented and evaluated 
35. Resource needs are identified 
36. Regular reviews of needed vs available resources are conducted 
37. Clear process for adding resources and/or changing priorities to reduce workload 
in the event there are not enough resources to meet the need 
38. Timelines are developed and maintained 
39. Timeline projected vs actuals tracked (particularly for critical path) 
40. Clear escalation process if timelines exceed agreed upon thresholds 
41. Organization has timeline templates with standard durations 
42. Organization has the ability to conduct scenario planning 
43. Timelines are used to decrease overall development duration 
44. Organization provides training for team members including team 
tools/processes/best practices, e.g., critical path understanding 
45. PM training leverages Project Management Body of Knowledge (PMBOK) 
46. Organization provides Just-in-Time (JIT) training (i.e., relevant training is 
provided just before needed) 
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Organizational Structure 
47. Organization has clear escalation pathways 
48. Organization has clear decision making pathways 
49. Decisions in my organization are unambiguous and specific 
50. Decisions in my organization are documented and readily retrievable 
51. Cross-functional teams make product development faster, cheaper, and/or higher 
quality 
52. Cross-functional teams in my organization have a clear purpose and scope 
53. Team members have clear understanding of their role 
54. Organizational best practices are established which are appropriate to the 
product development phase 
55. Organizational best practices are leveraged to quickly set up teams, tools, and 
processes 
56. Organizational best practices lead to decreased product development time 
57. Organizational best practices are continuously improved through process 
improvement initiatives 
58. Organization effectively leverages partnerships to extend resources and/or 
capabilities 
59. Organization effectively leverages partnerships to share and/or reduce risks 
60. Organization has the right-sized infrastructure in place to support projects 
 
PMO Components 
61. Does your organization have a formal PMO 
62. Roles are clearly defined for PM and team members 
63. PM's scope is cross-functional 
64. PMs ensure teams meet organizational objectives/goals 
65. PMs ensure portfolio and product strategies are developed 
66. PMs help teams think strategically 
67. Organization has and uses established methodologies, processes, tools, and 
training 
68. Organization leverages PMBOK practices 
69. PMs assist in establishing agreed upon goals and objectives 
70. PMs assist in establishing agreed upon product development plans 
71. PMs track organizational progress against goals and objectives 
72. PMs escalate issues as appropriate 
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8.3 Reference Standard and Rubric Development 
8.3.1 Reference Standard 
Table 11: Soft Skills Terms 
Communication: 
General 
Communication: 
PM Specific 
Communication: 
Team 
Management 
Strategy Experience General 
Direct Needs to be able 
to communicate 
at all levels 
internally and 
externally ("PM 
and Project Lead, 
cross-department, 
can communicate 
at all ends, up 
and outward, 
bottom up to top 
down, 
executives") 
Escalation tactics 
for obtaining a 
response from 
team members 
(Face to Face, 
telecom) 
Prioritization 
at program 
level 
Combination 
of formal 
training and 
hands on 
experience 
with feedback 
Soft 
skills are 
more 
important 
than 
hard 
skills 
Flexibility Effectively able to 
communicate 
constraints and 
potential solutions 
(Communicates 
why things can't 
be done, if can't 
be done ask for 
more resources) 
to Management 
Take "pulse" at 
team meetings 
Trade-offs at 
program and 
portfolio level 
Experience  
Humble Communicates 
issues across 
team 
Stop/Control 
conversation in 
meetings 
Leveraging 
Competitive 
intelligence to 
inform 
strategy 
  
Sense of humor Show pros/cons 
of mitigations 
    
Timeliness 
("quick") 
Real-time 
knowledge of 
project, high level 
    
Concise Able to 
communicate bad 
news 
    
Precise Regularly check-
ins with 
stakeholders 
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Table 12: Hard Tools Terms 
Processes: 
Budget 
Processes: 
Deliverables 
Management 
Processes: 
Meeting 
Management 
Processes: 
Resource 
Management 
Processes: 
Timelines 
Processes: 
Training 
Annual 
budget and 
five-year 
plan 
developed 
and current 
Clear 
identification 
of project 
deliverables 
Keep number 
of team 
members to a 
minimum 
Identification 
of resource 
needs 
Develop & 
maintain 
timelines 
Have training for 
team members 
which includes team 
tools/processes/best 
practices, e.g., 
critical path 
understanding 
Portfolio of 
Projects 
funded 
based on 
probability 
of success 
Clear 
identification 
of who's 
responsible for 
what project 
deliverables 
Meeting 
agendas and 
minutes: 
developed 
and 
distributed in a 
timely manner 
Regular 
evaluation of 
resource 
needs relative 
to available 
resources 
Track actuals 
against 
projected, 
particularly for 
critical path 
PM training 
leverages Project 
Management Body 
of Knowledge 
(PMBOK) 
Track 
actuals 
against 
budget 
Track project 
deliverables 
against 
internal and 
external 
commitments 
ADI logs 
maintained 
Mechanism 
for decision 
making if 
more 
resources are 
required than 
available to 
either 1) add 
more staff or 
2) change 
priorities to 
reduce 
workload 
Mechanism 
for escalating 
if timelines 
exceed 
agreed upon 
thresholds 
Just in time (JIT) 
training (i.e., 
conducted before 
using) 
Cost 
modeling (to 
inform 
budget) 
Mechanism for 
escalating if 
project 
deliverables 
not tracking to 
meet internal 
and external 
commitments 
Risks 
evaluated and 
documented 
 Timeline 
templates with 
standard 
durations  
 
    Ability to 
conduct 
scenario 
planning 
 
    Timelines 
leveraged to 
find ways to 
shorten 
overall 
development 
duration 
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Table 13: Organizational Structure Terms 
Governance Matrix 
organization: 
Teams 
Efficiencies Alliance 
Management 
General 
Clear 
communication 
pathways 
Cross-functional 
teams make 
product 
development 
faster, cheaper, 
and/or higher 
quality 
Have established 
organizational best 
practices which are 
right sized to the 
project phase 
Effectively 
leverage 
partnerships to 
extend resources 
and/or capabilities 
Right-sized 
infrastructure set-
up and in place to 
support projects 
Clear decision 
making process 
Teams have a 
clear purpose and 
scope 
Leverage 
organizational best 
practices to 
facilitate quickly 
setting up teams, 
tools and 
processes 
Effectively 
leverage 
partnerships to 
share and/or 
reduce risks 
 
Decisions are 
unambiguous and 
specific 
Team members 
understand their 
role 
Organizational 
best practices lead 
to decreased 
product 
development time 
  
Decisions are 
documented & 
readily retrievable 
 Continuously 
improve through 
process 
improvement 
initiatives 
  
 
Table 14: PMO Components Terms 
PM Role: General PM Role: Strategic Methodologies Alignment 
Role is clearly defined 
both for PM and other 
roles with which the PM 
interacts 
Ensures portfolio and 
product strategy 
developed 
Established 
methodologies, 
including processes, 
tools and training 
Help establish agreed 
upon goals and 
objectives 
Scope is cross-
functional 
Helps teams think 
strategically 
Methodologies 
appropriately leverage 
PMBOK practices 
Helps establish agreed 
upon product 
development plan 
Responsible for 
ensuring team meets 
organizational 
objectives/goals 
  Tracks progress against 
goals and objectives 
PM Role: General   Escalates issues as 
appropriate 
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8.3.2 Rubric Development 
Table 15: Soft Skills Attributes 
Communication: 
General 
Communication: 
PM Specific 
Communication: 
Team 
Management 
Strategy Experience General 
Communications 
in my organization 
are direct and to 
the point without 
being rude 
PMs are effective 
at communicating 
information 
internally and 
externally (e.g., 
teams, 
management, 
outside company, 
etc.) 
PMs leverage 
multiple 
communication 
methods 
effectively to 
obtain responses 
from team 
members 
Programs 
are 
prioritized at 
a portfolio 
level 
Organization 
provides 
opportunities 
for both 
formal 
training and 
hands on 
experience 
(including 
feedback) 
Soft skills 
are highly 
valued 
Messages are 
tailored to the 
audience 
PMs are effective 
at communicating 
constraints and 
potential 
solutions 
PMs check the 
"pulse" of the 
team during 
meetings 
Trade-off 
decisions 
factor in both 
program and 
portfolio 
levels 
  
Messages are 
conveyed with 
humility 
PMs are effective 
at ensuring 
issues are 
appropriately 
shared across 
teams 
PMs are able to 
guide team 
meeting 
discussions so 
they remain 
constructive and 
productive 
Competitive 
intelligence 
is used to 
inform 
portfolio and 
product 
strategy 
  
Humor is used 
appropriately in 
communications 
PMs are able to 
effectively share 
the pros and 
cons of 
mitigations 
    
Information is 
shared in a timely 
manner 
PMs have real-
time, high level 
knowledge of the 
project 
    
Information 
sharing is concise 
PMs are able to 
effectively 
communicate 
bad news 
    
Information 
sharing is precise 
PMs regularly 
check in with 
stakeholders 
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Table 16: Hard Tools Attributes 
Processes: 
Budget 
Processes: 
Deliverables 
Management 
Processes: 
Meeting 
Management 
Processes: 
Resource 
Management 
Processes: 
Timelines 
Processes: Training 
My 
organization 
has a current 
annual 
budget and 
five-year plan 
Projects have 
clearly 
identified 
deliverables 
Team 
members are 
kept to a 
minimum 
Resource 
needs are 
identified 
Timelines are 
developed 
and 
maintained 
Organization 
provides training for 
team members 
including team 
tools/processes/best 
practices, e.g., critical 
path understanding 
Projects are 
funded based 
on probability 
of success at 
the portfolio 
level 
Responsibility 
for project 
deliverables is 
clearly 
identified 
Meeting 
agendas and 
minutes are 
developed 
and 
distributed in 
a timely 
manner 
Regular 
reviews of 
needed vs 
available 
resources are 
conducted 
Timeline 
projected vs 
actuals 
tracked 
(particularly 
for critical 
path) 
PM training 
leverages Project 
Management Body of 
Knowledge (PMBOK) 
Organization 
tracks actuals 
against 
budget 
Delivery of 
project 
deliverables is 
tracked 
against 
internal and 
external 
commitments 
Action Item, 
Decision and 
Issues (ADI) 
logs are 
maintained 
Clear process 
for adding 
resources 
and/or 
changing 
priorities to 
reduce 
workload in 
the event 
there are not 
enough 
resources to 
meet the 
need 
Clear 
escalation 
process if 
timelines 
exceed 
agreed upon 
thresholds 
Organization 
provides Just-in-Time 
(JIT) training (i.e., 
relevant training is 
provided just before 
needed) 
Cost 
modeling & 
forecasting is 
used to 
inform budget 
and five-year 
plan 
Clear process 
for escalating 
potential 
delays in 
meeting 
project 
deliverables 
per internal 
and external 
commitments 
Risks are 
documented 
and evaluated 
 Organization 
has timeline 
templates 
with standard 
durations 
 
    Organization 
has the ability 
to conduct 
scenario 
planning 
 
    Timelines are 
used to 
decrease 
overall 
development 
duration 
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Table 17: Organizational Structure Attributes 
Governance Matrix 
organization: 
Teams 
Efficiencies Alliance 
Management 
General 
Organization has 
clear escalation 
pathways 
Cross-functional 
teams make 
product 
development 
faster, cheaper, 
and/or higher 
quality 
Organizational 
best practices are 
established which 
are appropriate to 
the development 
phase 
Organization 
effectively 
leverages 
partnerships to 
extend resources 
and/or capabilities 
Organization has 
the right-sized 
infrastructure in 
place to support 
projects 
Organization has 
clear decision 
making pathways 
Cross-functional 
teams in my 
organization have 
a clear purpose 
and scope 
Organizational 
best practices are 
leveraged to 
quickly set up 
teams, tools, and 
processes 
Organization 
effectively 
leverages 
partnerships to 
share and/or 
reduce risks 
 
Decisions in my 
organization are 
unambiguous and 
specific 
Team members 
have clear 
understanding of 
their role 
Organizational 
best practices lead 
to decreased 
product 
development time 
  
Decisions in my 
organization are 
documented and 
readily retrievable 
 Organizational 
best practices are 
continuously 
improved through 
process 
improvement 
initiatives 
  
 
Table 18: PMO Components Attributes 
PM Role: General PM Role: Strategic Methodologies Alignment 
Roles are clearly 
defined for PM and 
team members 
PMs ensure portfolio 
and product strategies 
are developed 
Organization has and 
uses established 
methodologies, 
processes, tools, and 
training 
PMs assist in 
establishing agreed 
upon goals and 
objectives 
PM's scope is cross-
functional 
PMs help teams think 
strategically 
Organization leverages 
PMBOK practices 
PMs assist in 
establishing agreed 
upon product 
development plans 
PMs ensure teams 
meet organizational 
objectives/goals 
  PMs track 
organizational progress 
against goals and 
objectives 
   PMs escalate issues as 
appropriate 
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9 Supplementary Figures and Tables 
Table 19: Term count by company identifier and top level category 
Company Soft 
Skills 
Hard 
Tools 
Organizational 
Structure 
PMO 
Components 
Total 
1 16 60 33 18 33 
2 14 6 5 5 5 
3 5 7 9 15 9 
4 14 7 12 2 12 
5 17 8 6 6 6 
6 0 1 6 7 6 
7 3 24 5 2 5 
8 5 4 1 5 1 
9 3 0 14 7 14 
10 10 10 13 12 13 
11 10 5 6 11 6 
12 5 2 8 3 8 
13 14 16 11 6 11 
14 11 1 6 3 6 
15 15 6 2 2 2 
Total 142 157 137 104 540 
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Figure 6a-d: Phase I term counts and reference standard definition cut-off 
Top level categories by attribute and company size with the cut-off (>6) for the reference standard applied. 
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Figure 7a-d: Phase II survey results (raw data) 
Phase II survey responses providing assessment of company’s performance (percentage) relative to each attribute. 
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Figure 8a-d: Phase II survey results (mean) and evaluation cut-off 
Phase II comparator company survey results by top level categories relative to evaluation cut-off (>3.0 as indicated by the red line).  
